Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Berntorp

Showing results (1-10 of 250) with videos related to

Pageof 25
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 5, 1999
Guidelines on treatment of haemophilia in SwedenE Berntorp
Annals of Hematology|January 1, 1994
Viral safety issues: plasma-derived factor VIIIE Berntorp
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 17, 2008
Prophylaxis in von Willebrand diseaseE Berntorp
Haematologica|February 24, 2001
Regimens of factor VIII administration--continuous infusion vs. bolusE Berntorp
Lakartidningen|March 31, 2000
[Reply: effects and side-effects of the length of therapy]E Berntorp
Seminars in Thrombosis and Hemostasis|November 25, 2000
Recombinant FVIIa in the treatment of warfarin bleedingE Berntorp
Seminars in Hematology|July 13, 2001
The concern of viral safety in the treatment of hemophiliaE Berntorp
Thrombosis and Haemostasis|June 1, 1994
Impact of replacement therapy on the evolution of HIV infection in hemophiliacsE Berntorp
Thrombosis and Haemostasis|July 1, 1997
Second generation, B-domain deleted recombinant factor VIIIE Berntorp
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Methods of haemophilia care delivery: regular prophylaxis versus episodic treatmentE Berntorp
Pageof 25

Showing results (1-10 of 250) with videos related to

Sort By:
Pageof 25
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 5, 1999
Guidelines on treatment of haemophilia in SwedenE Berntorp
Annals of Hematology|January 1, 1994
Viral safety issues: plasma-derived factor VIIIE Berntorp
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 17, 2008
Prophylaxis in von Willebrand diseaseE Berntorp
Haematologica|February 24, 2001
Regimens of factor VIII administration--continuous infusion vs. bolusE Berntorp
Lakartidningen|March 31, 2000
[Reply: effects and side-effects of the length of therapy]E Berntorp
Seminars in Thrombosis and Hemostasis|November 25, 2000
Recombinant FVIIa in the treatment of warfarin bleedingE Berntorp
Seminars in Hematology|July 13, 2001
The concern of viral safety in the treatment of hemophiliaE Berntorp
Thrombosis and Haemostasis|June 1, 1994
Impact of replacement therapy on the evolution of HIV infection in hemophiliacsE Berntorp
Thrombosis and Haemostasis|July 1, 1997
Second generation, B-domain deleted recombinant factor VIIIE Berntorp
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Methods of haemophilia care delivery: regular prophylaxis versus episodic treatmentE Berntorp
Pageof 25